DGAP-News: MediClin AG: Group sales for the 1st quarter of 2022 significantly above the previous year's figure
DGAP-News: MediClin AG
/ Key word(s): Quarterly / Interim Statement
MediClin AG: Group sales for the 1st quarter of 2022 significantly above the previous year's figure
02.05.2022 / 12:40
The issuer is solely responsible for the content of this announcement.
Offenburg, 2 May 2022
Group sales for the 1st quarter of 2022 significantly above the previous year's figure
In the 1st quarter of 2022, the continuous improvement in occupancy rates in the rehabilitation clinics, which began in the second half of 2021, continued despite high incidences.
"Although the increase in Group sales over the first quarter of 2021 must be regarded in the context of the extremely weak prior-year quarter, the sales development in the first months of the year under review is nevertheless positive", commented Tino Fritz, CFO of MEDICLIN, on the current business development and added: "But we have also felt a significant increase in costs".
In the first quarter of 2022, Group sales of EUR 174.2 mill. were EUR 17.8 mill. or 11.4 % above the comparable prior-year quarter. On the costs side, the cost of raw materials and consumables used was EUR 5.3 mill. or 18.6 % above the prior-year value. At plus EUR 4.0 mill., energy costs and laboratory tests account for the major share in the increase in raw materials and consumables used. Staff costs rose only moderately by EUR 0.9 mill. or 0.8 %.
"At present, we assume that the pandemic will not have a significantly negative impact on the occupancy in the next two quarters, but we must assume that the much higher material expenses compared to the previous year will have a negative impact on earnings", said Dr. Joachim Ramming, CEO of MEDICLIN. However, he is confident that the development of sales and earnings on the back of rising demand for medical, therapeutic and nursing care services will lead to an increase in sales and earnings in the Group, provided that the consequences and effects of Russia's invasion of Ukraine will have no massive and lasting negative effect on the German economy.
The interim report as of 31 March 2022 is available from today under www.mediclin.de in German and English.
/
About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 35 clinics, seven care facilities and eleven medical care centers. The Group has around 8,350 beds/care places and employs around 10,200 people. In a strong network, MEDICLIN offers the pa-tient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDI-CLIN designs the care and support of people in need of care according to their individual needs and per-sonal needs.
MEDICLIN ─ a company of the Asklepios Group.
02.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
MediClin AG |
|
Okenstraße 27 |
|
77652 Offenburg |
|
Germany |
Phone: |
+49 (0)781 488-326 |
Fax: |
+49 (0)781 488-184 |
E-mail: |
[email protected] |
Internet: |
www.mediclin.de |
ISIN: |
DE0006595101 |
WKN: |
659510 |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1341131 |
|
End of News |
DGAP News Service |
1341131 02.05.2022
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
609,08 |
645,11 |
673,09 |
659,86 |
673,14 |
704,70 |
730,07 |
EBITDA1,2 |
27,01 |
37,35 |
93,58 |
77,50 |
85,22 |
90,92 |
98,73 |
EBITDA-Marge3 |
4,43 |
5,79 |
13,90 |
11,74 |
12,66 |
12,90 |
|
EBIT1,4 |
6,62 |
15,06 |
22,41 |
0,15 |
11,56 |
19,52 |
12,72 |
EBIT-Marge5 |
1,09 |
2,33 |
3,33 |
0,02 |
1,72 |
2,77 |
1,74 |
Jahresüberschuss1 |
3,96 |
7,76 |
9,68 |
-0,04 |
1,49 |
9,72 |
-10,72 |
Netto-Marge6 |
0,65 |
1,20 |
1,44 |
-0,01 |
0,22 |
1,38 |
-1,47 |
Cashflow1,7 |
19,34 |
29,77 |
69,59 |
118,69 |
81,97 |
34,64 |
78,00 |
Ergebnis je Aktie8 |
0,08 |
0,16 |
0,20 |
-0,19 |
0,03 |
0,20 |
-0,23 |
Dividende8 |
0,05 |
0,05 |
0,05 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Mediclin |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
659510 |
2,600 |
Halten |
123,50 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
10,00 |
19,19 |
0,52 |
19,55 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,63 |
1,58 |
0,17 |
1,45 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
06.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
02.05.2025 |
31.07.2024 |
04.11.2024 |
28.03.2025 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
7,08% |
1,48% |
-5,11% |
-1,52% |
|
|